Additionally, we reveal a regulatory mechanism for this RNP complex in MM, acting through the enhanced H3K27me3 activity of PRC2 complex, which in turn drives chemoresistance via the FOXO3/ZFP36/UPR pathway axis (Fig. 7n). This evidence concerns the gene FOXO3 and Miyoshi myopathy.